BUSINESS COMBINATION - Narrative (Details) $ / shares in Units, $ in Thousands		3 Months Ended		9 Months Ended		12 Months Ended	13 Months Ended
	Sep. 16, 2024 USD ($) contingentValueRight $ / shares	Sep. 30, 2025 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2025 USD ($)	Sep. 30, 2024 USD ($)	Dec. 31, 2024 USD ($)	Sep. 30, 2025 USD ($)
Business Combination [Line Items]
Selling, general and administrative expenses		$ 76,656	$ 79,075	$ 234,955	$ 179,917
Research and development expense		12,304	10,128	39,403	27,935
Alimera Sciences, Inc
Business Combination [Line Items]
Common Stock, par value (in dollars per share) | $ / shares	$ 0.01
Cash consideration per share (in dollars per share) | $ / shares	$ 5.50
Business combination, number of contingent value rights to be received | contingentValueRight	1
Repayment of Alimera Debt	$ 78,540
Payment of Alimera transaction costs	20,172
Payment of settlement of acquiree's equity awards	19,300
Cash paid at closing for settlement of equity awards	1,300
Cash settlement for pre-acquisition equity awards	9,535
Selling, general and administrative expenses						$ 8,800
Research and development expense						1,000
Fair value of CVRs	8,322
Business combination, contingent value rights	$ 8,700
Goodwill, Measurement Period Adjustment		2,100					$ 2,057
Payment of Alimera transaction costs		$ 400	$ 9,800	$ 1,600	$ 13,200
Alimera Sciences, Inc | Contingent Value Right
Business Combination [Line Items]
Selling, general and administrative expenses						$ 400